Tom Wilder - President and CEO.  Over 30 years of experience, having most recently led Sequent Medical, Inc., a neurovascular company that developed the WEB Aneurysm Embolization System, where he served for six years.  Sequent was acquired by Terumo Corporation in 2016 for up to $380 million.  Prior to joining Sequent, he was President and CEO of PhotoThera, Inc., a company that was developing a unique therapy for acute ischemic stroke patients.  Served as President and CEO of Micro Therapeutics, Inc. (MTIX), which was merged into ev3, Inc. (EVVV) in 2006, at a valuation of $360 million.  He served in positions of increasing responsibility at Medtronic, Inc. (MDT), most recently as Vice President and General Manager of its endovascular stent grafts division. He currently serves on the Board of Directors of Penumbra, Inc. (PEN) and Endologix, Inc. (ELGX).
Jon J. Snyder - Founder, Chief Business Officer.  Over 25 years of domestic and international management leadership experience in biomedical and healthcare sales, marketing,  operations, and venture capital investment at start-up and Fortune 500 (Top 20) companies including Cyberonics, Cardinal Health, Imalux, and STERIS Corporation. 

Zi-Ping Fang, Ph.D. - Chief Scientific Officer.  PhD in Biomedical Engineering focused on neurostimulation technology from Case Western Reserve University. Over 25 years of neurostimulation R&D, pre-clinical and clinical research leading to FDA approval, including technology leadership and management and executive responsibility in neurostimulation startup business development and operations including Nevro and NeuroControl.

Management Team